Ranitidine improves certain cellular immune responses in asymptomatic HIV-infected individuals.

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Human immunodeficiency virus (HIV) infection progressively impairs immunocompetence, leading to opportunistic infections and malignancies.
• Early HIV infection is characterized by specific immunological deficits.
• The potential for immunomodulation in HIV management is an area of active research.

Purpose of the Study:

• To investigate the immunomodulatory effects of oral ranitidine in HIV-positive patients.
• To assess the impact of ranitidine on key immunological parameters in early HIV infection.
• To determine if ranitidine can mitigate immune system decline associated with HIV.

Main Methods:

• A double-blind, placebo-controlled study involving 18 HIV-positive patients (CDC group II) without active infections.
• Patients received either oral ranitidine (600 mg daily) or a placebo for 28 days.
• Evaluation of immunological parameters including natural killer cell activity, T-cell blastogenesis, and soluble interleukin-2 receptors.

Main Results:

• Ranitidine treatment led to significant improvements in spontaneous and interleukin-2/interferon-alpha-stimulated natural killer cell activity compared to placebo.
• T-cell blastogenesis to phytohemagglutinin and serum soluble interleukin-2 receptors increased in the ranitidine group.
• No significant changes in CD4+ cell counts were observed with ranitidine treatment.
• Statistical significance was noted for improvements in natural killer cell activity (p<0.03, p<0.01, p<0.02) and T-cell blastogenesis (p<0.01).

Conclusions:

• Oral ranitidine demonstrated a modest but significant immunomodulatory effect in HIV-infected individuals.
• Ranitidine improved certain aspects of cellular immunity, including natural killer cell function and T-cell responses.
• Further clinical trials are warranted to explore the therapeutic potential of ranitidine in managing HIV-associated immune dysfunction.